El inhibidor selectivo de la ciclooxigenasa-2, etoricoxib, produce menos efectos secundarios gastrointestinales leves que diclofenaco en el tratamiento del dolor crónico articular. Proyecto Multinational Etoricoxib and Diclofenac Arthritis Long Term programme (MEDAL)

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Title: FMC - Formación Médica Continuada en Atención Primaria

Abbreviated Title: FMC - Formación Médica Continuada en Atención Primaria

Publisher: Elsevier BV

ISSN (Print): 11342072

Publication date Created: August 2007

Publication date (Print): August 2007

Volume: 14

Issue: 7

Page: 437

Article

DOI: 10.1016/S1134-2072(07)71874-1

SO-VID: a2fc34e2-8148-41c9-be8e-e272572df0b9

License:

https://www.elsevier.com/tdm/userlicense/1.0/

History

Data availability:

Comments

Comment on this article

scite_